SRNE - Sorrento gets FDA nod for early-stage COVID-19 antibody trial September, 17 2020 12:33 AM Sorrento Therapeutics Inc. Sorrento Therapeutics (NASDAQ:SRNE) receives FDA clearance to with its Phase 1 clinical trial for COVI-GUARD (STI-1499) in hospitalized COVID-19 patients.More news on: Sorrento Therapeutics, Inc., Read more ...